Connect with us

Cannabis News

Senator Blocks Confirmation Of Trump’s ‘Unqualified’ White House Drug Czar Pick Who Has Voiced Medical Marijuana Support

Published

on

A Democratic senator is holding back nearly 90 of President Donald Trump’s administration nominees, including the president’s pick for White House drug czar He says he is among many “unqualified” candidates who threaten to “undermine the rule of law and our national security.”

The Senate Judiciary Committee in October advanced the nomination of Sara Carter Bailey to join the administration as director of the Office of National Drug Control Policy (ONDCP). But when he was included in an en bloc confirmation package of 88 nominees, Sen. Michael Bennet (D-CO) raised a procedural question that led Republicans to stall the vote.

“I’ve just blocked 88 of Trump’s nominees for confirmation, including Sara Carter Bailey, the former Fox News contributor nominated to be our country’s drug czar,” Bennet said Thursday. “Bailey was nominated by Trump, who recently pardoned the former president of Honduras, who served 45 years in prison for conspiring to distribute more than 400 tons of cocaine.”

“I will not allow those without a candidate, this White House or the president to undermine the rule of law and our national security,” he said. he said.




The procedural complaint raised by Bennet relates to the ONDCP director being a “Tier I” executive officer.

Therefore, unlike the other candidates in the package, Bailey could not be included in the group vote – the body that was chaired by the Republican senator on Thursday. recognize.

Bailey, for his part, yes expressed his support for medical cannabis, while stating that he has “no problem” with legalizationeven if you may not personally agree with the policy.

A former journalist known for his coverage of drug cartels, Bailey also recently informed senators that the administration. keeping “all options” on the table as it continues to consider a proposal to reorganize marijuanawhile describing cannabis reform as a “bipartisan issue.”

Bennet isn’t the only senator questioning the nominee’s abilities. Before the committee’s vote in October, Sen. Dick Durbin (D-IL), the panel’s ranking member, called Bailey a Trump “loyalist” who was “appointed to a position that he is completely, utterly unqualified for.”

“He’s not a doctor or an addiction specialist,” she said. “He’s never been a prosecutor or a law enforcement officer.”

Given the ONDCP director’s role in setting and carrying out the administration’s agenda on drug policy issues, Bailey’s enthusiastic endorsement of medical cannabis in the past is welcome to advocates.

Senator Cory Booker (D-NJ) raised the issue of cannabis rescheduling one-on-one with the candidate in September, stating that the proposal to move marijuana from Schedule I to III of the Controlled Substances Act (CSA) would be a “step in the right direction.”

“It would open the door to more scientific research, so if you were to be confirmed, how would you advise the American president on the reprogramming process going on?” he asked.

Bailey said she shares Booker’s passion for the issue, which she described as “bipartisan.”

“If confirmed as director, I will comply with all federal laws and meet all legal responsibilities of ONDCP,” he said. “However, we will continue to work in depth with research and data. We will continue to do so and explore all options.”

Trump endorsed the redistricting on the campaign trail before his second term — as well as bank access to the marijuana industry and a ballot initiative to legalize Florida. But his latest comments in late August about the timing of the reorganization decision gave a more ambiguous impression of his stance on the matter.

While Bailey has spoken often on a variety of marijuana policy issues (focusing on illegal trafficking and illegal growing operations on US soil, for example), his public comments have been limited on how he personally feels about the issue. Last year, she said in an episode of her podcast, The Sara Carter Show, that she makes a distinction between legally regulated and illegally supplied marijuana.

“I don’t have a problem if it’s legalized and controlled,” he said. “I mean, maybe I have my own issues with how I feel about it, but I think it’s a wonderful way to handle cannabis for medicine and medical reasons — especially for people with cancer and other diseases, you know — to manage the disease and the side effects of those drugs and diseases. So I’m not saying we should make it illegal.”

If Bailey is ultimately confirmed by the Senate, he will be the second drug czar to come out in favor of medical marijuana. Former President Joe Biden’s ONDCP Director Rahul Guptaworked as a consultant to cannabis businesses and oversaw the implementation of West Virginia’s medical marijuana program.

On his social media, Bailey has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

the federal statute The drug czar is prohibited from agreeing to the legalization of Schedule I drugs in the CSA, including marijuana.

“The Director . . . shall ensure that federal funds appropriated to the Office of National Drug Control Policy shall not be expended for any study or contract related to the legalization (for medical use or any other use) of a substance listed in section I of section 812 of this title and shall take such measures as may be necessary to oppose any attempt to legalize the use (in any form) of a substance not listed in subparagraph (I)(B) of section 8 of section (I). The purpose of the Food and Drug Administration approved for medical use.

In April, on the other hand, the democratic members of Congress announced the introduction of a bill that would remove this restriction. It has yet to advance in the GOP-controlled Congress.

Bailey has separately sounded the alarm about the risk of pesticides and other contaminants in marijuana grown and sold by Chinese cartels…recently a House committee took up the matter.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

Last year, the candidate discussed the issue with Derek Maltz, a now-retired Drug Enforcement Administration (DEA) official who is serving as the agency’s interim administrator before his confirmation. Trump’s perennial pick, Terrance Cole.

In an X post about the interview with Maltz, Bailey said how “Chinese marijuana growing operations are using dangerous chemicals as pesticides.”

In 2022, U.S. Representative Mike Garcia (R-CA) praised Bailey for working with his office to bring attention to illegal grow operations in his district, leading to an investigation by local law enforcement.

Bailey credited congress, saying, “The work you’ve done to get rid of illegal marijuana seeds has prevented the cartels from exploiting your community, the people forced to work in it, and (your money).”

In a 2021 interview with Fox News’ Sean Hannity, he also talked about his work with Garcia, including accompanying him on a helicopter, “a lot of sophisticated illegal farms worth billions of dollars.”

The posters “have become much bolder. They are not afraid to hide,” he said. “They don’t hide it because they don’t feel like they’ll ever be held accountable for it.”

In a sense, Bailey seems to be implicitly suggesting that he supports regulated access to cannabis as a means to promote public safety and health. Whether that implied position would influence federal policy and whether the role of ONDCP director is confirmed and assumed remains to be seen.

On his social media, he has previously shared links (without comment) to news on various marijuana-related topics. In addition to his increased focus on illegal billboards, he has also published on congressional and state legalization votes, Biden administration staffers fired for cannabis use, Democratic presidential candidates’ support for legalization, progress on cannabis banking legislation in Congress, and state policy developments such as the legalization of cannabis cafes in Alaska.

Photo by Chris Wallis // Side Pocket Images.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

MMJDaily will be back August 10th

Published

on

By


Even the best growers need a dark cycle. MMJDaily is shutting down for the annual two-week summer break. There will be no newsletter in your inbox or new articles on the website for the next two weeks, but we will be back on August 10th. Thank you, as always, for following and supporting our work. Rest…

Continue Reading

Cannabis News

Adding Hemp To Dog Food Improves Digestive Health, New Study Shows

Published

on

By

A new study has found that adding hemp oil or a hemp seed byproduct to dog food can improve digestive health without negatively affecting the overall microbial system.

Research published in the journal Veterinary Sciences suggests that some types of hemp derivatives can be safely included as ingredients in dog food. However, the effects appear to depend in part on whether the cannabis is added as an oil or fiber supplement.

For the study, researchers at Kasetsart University in Thailand divided 24 mixed-breed dogs into three groups: one fed food with an 11 percent concentration of a high-fiber hemp seed byproduct, one received food containing 2 percent hemp seeds, and a third received a control diet without hemp.

The dogs were fed the diets for 90 days. The researchers compared the stool samples before the experiment and after 30 and 90 days. Genetic sequencing was used to track changes in gut bacterial composition and diversity.

Dogs fed hemp seed oil-infused food experienced a greater increase in microbial species richness.

“Hemp seeds modulate the canine microbiome without disrupting the ecological stability of the specific formulation, contributing to beneficial health effects in canine nutrition.”

The diet was also associated with increased levels of “beneficial” bacteria from the Lactobacillaceae family, and the fiber-rich hemp seed byproduct Actinobacteriota.

“Hemp seed derivatives altered the microbial composition by promoting beneficial bacteria that promoted gut health in dogs in a formulation-dependent manner,” the authors wrote, and the results “provide evidence for their inclusion as a functional ingredient in dog food.”

Despite the differences between the diets, 19 key bacterial collections were present throughout to analyze. And by day 90, the microbial composition also seemed to stabilize, indicating that the dietary supplements did not significantly disrupt the dogs’ intestinal systems.

Overall, the findings suggest that hemp seed ingredients can be safely incorporated into dog food while protecting gut health by promoting beneficial bacteria, the study authors said.

This is one of the latest studies on cannabis and its effects on dogs.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

For example, a systematic review of the scientific literature determined that studies “consistently show” this CBD is a potential “anti-cancer agent” in various types of cancer—and this effect applies to both dogs and humans.

The National Animal Supplement Council (NASC) sponsored a study in 2024 said that CBD is “safe for long-term use” in dogs—This is a significant finding given the emerging research that cannabis can effectively treat anxiety and certain skin conditions in dogs.

Another 2024 case study found this Cannabis appears to be a “viable alternative” treatment option for dogs suffer from a common skin disease, especially if they suffer from the adverse side effects of conventional steroid therapies.

Meanwhile, previous research suggests that Giving dogs a dose of CBD can help reverse the ill effects of accidental THC consumptionaccording to a study by the authors titled “First report of treatment of THC toxicosis in dogs with administration of CBD.”

Another study published in 2024 found that Dogs receiving daily doses of CBD see “significant reductions” in stress and anxiety related to car trips.

Other studies have demonstrated the benefits of CBD, such as the frequency of seizures among dogs receiving the cannabinoid is reduced. Moreover, a study published in 2018 found this dogs with arthritis see improvements with CBD treatment.

As for other animals, it was discovered by the US Department of Agriculture (USDA) in 2013 Cows fed hempseed cake maintain very low concentrations of THC and CBD in their bodies, indicating that meat products from hemp-fed cows are safe for human consumption.

Another federally funded study published in 2022 found this Feeding hemp to cows reduces stress.

It has also been studied by researchers How CBD affects stress and pain in horses.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Ora Pharm affirms uninterrupted access to Helius products

Published

on

By

Ora Pharm has confirmed that New Zealand patients, prescribers and pharmacies continue to have uninterrupted access to Helius Therapeutics products following the successful acquisition of the business and its key assets, directly challenging the misinformation being circulated to patients and prescribers by cannabis importer MW Pharma Limited (trading as NUBU).

Industry monitoring was highlighted on Monday, July 20th, when Helius Therapeutics announced that NZ Grow Co. As he inaugurated Growers Day. The event demonstrated the full operational strength, advanced capabilities and integrated supply chain now fully operational under Ora Pharm’s leadership to support the growth of the NZ sector.

At the event, CEO Zoë Reece addressed concerns stemming from a July 9 industry bulletin distributed by NUBU, which stated that “Helius Therapeutics has ceased production and all products are now discontinued.”

© Ora Pharm

Ora Pharm said the statement was incorrect and had the potential to create unnecessary uncertainty in a highly regulated healthcare sector.

“Inaccurate information about the availability of medicines can cause unnecessary worry for patients, prescribers and pharmacies, interfere with treatment decisions and undermine confidence in the New Zealand cannabis industry.”

Ora Pharm completed the business and acquisition of key assets of Helius Therapeutics on June 18, 2026, resuming manufacturing, packaging and nationwide distribution the following day. All Helius brand formulated products and locally grown products remain approved and available for patient supply.

CEO Zoë Reece said the company’s focus is on ensuring continuity of care while strengthening New Zealand’s medicinal cannabis industry.

“The Helius facility gives New Zealand growers direct access to world-class pharmaceutical drying, extraction and manufacturing capabilities. Combined with NZ Grow Co., we are creating a secure and integrated pathway from cultivation to finished products and international markets. Our focus is on clinical continuity, quality assurance and confidence in patients and prescribing physicians every day.”

© Ora Pharm

The integration of the GMP-certified Auckland manufacturing facility with NZ Grow Co.’s cultivation network creates New Zealand’s largest medicinal cannabis supply chain. This unified network insulates domestic patients from volatile international import dependencies while providing independent local growers with a transparent, high-standard route to export markets.

Ora Pharm remains committed to working collaboratively across the sector to support patient access, strengthen confidence in the New Zealand cannabis industry and continue to invest in New Zealand’s pharmaceutical manufacturing capacity.

For more information:
Ora Pharm
(email protected)
www.orapharm.co.nz

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media